Restricted accessResearch articleFirst published online 2018-9-11
The Level of Plasma Amyloid-β 40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study
Transport proteins, soluble low-density lipoprotein receptor-related protein-1 (sLRP1), and soluble receptor of advanced glycation end products (sRAGE), play an important role in the clearance of plasma amyloid-β (Aβ). However, their relationship is not clear.
Objective:
The aim was to explore the relationship between plasma levels of sLRP1, sRAGE, and Aβ in a cross-sectional study.
Methods:
A total of 1,185 cognitively normal participants (age above 40) from a village in the suburbs of Xi’an, China were enrolled from October 8, 2014 to March 30, 2015. Plasma Aβ40, Aβ42, sLRP1, and sRAGE were tested using a commercial ELISA. Apolipoprotein E (APOE) genotyping was conducted using PCR and sequencing. The relationship between plasma levels of sLRP1, sRAGE, and Aβ was analyzed using Pearson’s correlation analysis and multiple linear regression.
Results:
In the total population, Log sLRP1 and Log sRAGE were positively correlated with plasma Aβ40 (r= 0.103, p < 0.001; r= 0.064, p = 0.027, respectively), but neither were associated with plasma Aβ42. After multivariable adjustment in the regression model, Log sLRP1 and Log sRAGE were still positively related with plasma Aβ40 (β= 2.969, p < 0.001; β= 1.936, p = 0.017, respectively) but not Aβ42. Furthermore, the positive correlations between transport proteins and plasma Aβ40 remained significant only in APOEɛ4 non-carriers after Pearson’s analysis and multiple regression analysis after stratification by gene status.
Conclusion:
The concentrations of plasma sLRP1 and sRAGE had a significant impact on the level of plasma Aβ40 in cognitively normal adults, especially in APOEɛ4 non-carriers. However, the mechanism by which the transport proteins are involved in peripheral Aβ clearance and the relationship between transporters and amyloid burden in the brain needs further validation.
SelkoeDJ (1994) Alzheimer’s disease: A central role for amyloid. J Neuropathol Exp Neurol53, 438–447.
2.
SelkoeDJ (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci17, 489–517.
3.
YounkinSG (1995) Evidence that A beta 42 is the real culprit in Alzheimer’s disease. Ann Neurol37, 287–288.
4.
IwatsuboT, MannDM, OdakaA, SuzukiN, IharaY (1995) Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol37, 294–299.
5.
Tarasoff-ConwayJM, CarareRO, OsorioRS, GlodzikL, ButlerT, FieremansE, AxelL, RusinekH, NicholsonC, ZlokovicBV, FrangioneB, BlennowK, MenardJ, ZetterbergH, WisniewskiT, de LeonMJ (2015) Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol11, 457–470.
6.
KawarabayashiT, YounkinLH, SaidoTC, ShojiM, AsheKH, YounkinSG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci21, 372–381.
FandosN, Perez-GrijalbaV, PesiniP, OlmosS, BossaM, VillemagneVL, DoeckeJ, FowlerC, MastersCL, SarasaM (2017) Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst)8, 179–187.
9.
OvodV, RamseyKN, MawuenyegaKG, BollingerJG, HicksT, SchneiderT, SullivanM, PaumierK, HoltzmanDM, MorrisJC, BenzingerT, FaganAM, PattersonBW, BatemanRJ (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement13, 841–849.
10.
DeMattosRB, BalesKR, CumminsDJ, DodartJC, PaulSM, HoltzmanDM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A98, 8850–8855.
GhisoJ, ShayoM, CaleroM, NgD, TomidokoroY, GandyS, RostagnoA, FrangioneB (2004) Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J Biol Chem279, 45897–45908.
13.
GhisoJ, CaleroM, MatsubaraE, GovernaleS, ChubaJ, BeavisR, WisniewskiT, FrangioneB (1997) Alzheimer’s soluble amyloid beta is a normal component of human urine. FEBS Lett408, 105–108.
14.
YamagishiS, MatsuiT (2010) Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed)2, 1184–1195.
15.
LiangF, JiaJ, WangS, QinW, LiuG (2013) Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer’s disease. J Clin Neurosci20, 357–361.
16.
EmanueleE, D’AngeloA, TomainoC, BinettiG, GhidoniR, PolitiP, BernardiL, MalettaR, BruniAC, GeroldiD (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol62, 1734–1736.
17.
LiK, DaiD, ZhaoB, YaoL, YaoS, WangB, YangZ (2010) Association between the RAGE G82S polymorphism and Alzheimer’s disease. J Neural Transm (Vienna)117, 97–104.
18.
HoltzmanDM (2001) Role of apoe/Abeta interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy. J Mol Neurosci17, 147–155.
ShangS, LiP, DengM, JiangY, ChenC, QuQ (2016) The age-dependent relationship between blood pressure and cognitive impairment: A cross-sectional study in a rural area of Xi’an, China. PLoS One11, e0159485.
21.
KatzmanR, ZhangMY, Ouang YaQ, WangZY, LiuWT, YuE, WongSC, SalmonDP, GrantI (1988) A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol41, 971–978.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edition, American Psychiatric Association, Washington, DC.
24.
OhES, TroncosoJC, Fangmark TuckerSM (2008) Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer’s disease. Neuromolecular Med10, 195–207.
25.
JiangY, ShangS, LiP, ChenC, DangL, WangJ, HuoK, DengM, WangJ, QuQ (2018) Pulse pressure is associated with plasma amyloid-beta transport dysfunction. J Hypertens36, 569–579.
FaganAM, MintunMA, MachRH, LeeSY, DenceCS, ShahAR, LaRossaGN, SpinnerML, KlunkWE, MathisCA, DeKoskyST, MorrisJC, HoltzmanDM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol59, 512–519.
34.
NilssonLN, GografeS, CostaDA, HughesT, DresslerD, PotterH (2012) Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimer’s disease. Technol Innov14, 199–208.
35.
SharmanMJ, MoriciM, HoneE, BergerT, TaddeiK, MartinsIJ, LimWL, SinghS, WenkMR, GhisoJ, BuxbaumJD, GandyS, MartinsRN (2010) APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis21, 403–409.
36.
TatenoA, SakayoriT, KimWC, KoedaM, KumitaS, SuzukiH, OkuboY (2017) Effect of apolipoprotein E phenotype on the association of plasma amyloid beta and amyloid positron emission tomography imaging in Japan. Alzheimers Dement (Amst)9, 51–56.
37.
SwaminathanS, RisacherSL, YoderKK, WestJD, ShenL, KimS, InlowM, ForoudT, JagustWJ, KoeppeRA, MathisCA, ShawLM, TrojanowskiJQ, SoaresH, AisenPS, PetersenRC, WeinerMW, SaykinAJ (2014) Association of plasma and cortical amyloid beta is modulated by APOE epsilon4 status. Alzheimers Dement10, e9–e18.
38.
BachmeierC, ParisD, Beaulieu-AbdelahadD, MouzonB, MullanM, CrawfordF (2013) A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis11, 13–21.
39.
BellRD, WinklerEA, SinghI, SagareAP, DeaneR, WuZ, HoltzmanDM, BetsholtzC, ArmulikA, SallstromJ, BerkBC, ZlokovicBV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature485, 512–516.
